Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand

Thyroid

Volumn 23, Issue 1, 2013, Pages 70-78

  Li, Liang Cheng ^a   Jayarama, Shankara ^a   Pilli, Tania ^a,b   Qian, Lixia ^a   Pacini, Furio ^b   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DEATH RECEPTOR; DECOY RECEPTOR 3; MADD PROTEIN; ONCOPROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CHROMONES; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 84872066280     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0155     Document Type: Article

References (32)

1. Kim CS, Zhu X 2009 Lessons from mouse models of thyroid cancer. Thyroid 19:1317-1331.
2. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393-1400.
3. Nagane M, Huang HJ, Cavenee WK 2001 The potential of TRAIL for cancer chemotherapy. Apoptosis 6:191-197. (Pubitemid 32423728)
4. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J 2000 TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2:241-243.
5. Wang SH, Mezosi E, Wolf JM, Cao Z, Utsugi S, Gauger PG, Doherty GM, Baker JR, Jr. 2004 IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene 23:928-935. (Pubitemid 38250938)
6. Zhang L, Fang B 2005 Mechanisms of resistance to TRAILinduced apoptosis in cancer. Cancer Gene Ther 12:228-237. (Pubitemid 40315182)
7. Park JW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH 2003 Modulation of tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. Thyroid 13:1103-1110. (Pubitemid 38032395)
8. Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS 2011 Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol 205:362-e12-362-e25.
9. Li P, Jayarama S, Ganesh L, Mordi D, Carr R, Kanteti P, Hay N, Prabhakar BS 2010 Akt-phosphorylated mitogenactivated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem 285:22713-22722.
10. Subramanian M, Pilli T, Bhattacharya P, Pacini F, Nikiforov YE, Kanteti PV, Prabhakar BS 2009 Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab 94:1467-1471.
11. Kurada BR, Li LC, Mulherkar N, Subramanian M, Prasad KV, Prabhakar BS 2009 MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. J Biol Chem 284:13533-13541.
12. Prabhakar BS, Mulherkar N, Prasad KV 2008 Role of IG20 splice variants in TRAIL resistance. Clin Cancer Res 14:347-351. (Pubitemid 351226099)
13. Li LC, Sheng JR, Mulherkar N, Prabhakar BS, Meriggioli MN 2008 Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res 68:7352-7361.
14. Mulherkar N, Ramaswamy M, Mordi DC, Prabhakar BS 2006 MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Oncogene 25:6252-6261. (Pubitemid 44564742)
15. Al-Zoubi AM, Efimova EV, Kaithamana S, Martinez O, El-Idrissi Mel A, Dogan RE, Prabhakar BS 2001 Contrasting effects of IG20 and its splice isoforms, MADD and DENNSV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3. J Biol Chem 276:47202-47211.
16. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341. (Pubitemid 352789529)
17. Simon P 2003 Q-Gene: processing quantitative real-time RTPCR data. Bioinformatics 19:1439-1440. (Pubitemid 36939825)
18. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, De Forge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
19. Ashkenazi A, Dixit VM 1999 Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260. (Pubitemid 29164042)
20. Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS 2004 IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Oncogene 23:6083-6094. (Pubitemid 39178861)
21. Karga H, Lee JK, Vickery AL, Jr., Thor A, Gaz RD, Jameson JL 1991 Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832-836. (Pubitemid 21921945)
22. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA 1994 Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30 A: 987-993. (Pubitemid 24256250)
23. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F 2000 N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19-23. (Pubitemid 30090361)
24. Fagin JA 2002 Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16:903-911. (Pubitemid 34478529)
25. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA 2000 The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19:3948-3954. (Pubitemid 30658985)
26. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3-CA, and AKT1. Cancer Res 69:4885-4893.
27. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE 2007 A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444. (Pubitemid 47123510)
28. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, Ringel MD 2005 AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146:4456-4463. (Pubitemid 41324044)
29. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD 2004 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41:161-170. (Pubitemid 38333792)
30. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix. (Pubitemid 351698084)
31. Shinohara M, Chung YJ, Saji M, Ringel MD 2007 AKT in thyroid tumorigenesis and progression. Endocrinology 148:942-947.
32. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C 2011 Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 96:E2063-E2071.